Literature DB >> 17576866

Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study.

Caroline S Fox1, Joseph M Massaro, Udo Hoffmann, Karla M Pou, Pal Maurovich-Horvat, Chun-Yu Liu, Ramachandran S Vasan, Joanne M Murabito, James B Meigs, L Adrienne Cupples, Ralph B D'Agostino, Christopher J O'Donnell.   

Abstract

BACKGROUND: Visceral adipose tissue (VAT) compartments may confer increased metabolic risk. The incremental utility of measuring both visceral and subcutaneous abdominal adipose tissue (SAT) in association with metabolic risk factors and underlying heritability has not been well described in a population-based setting. METHODS AND
RESULTS: Participants (n=3001) were drawn from the Framingham Heart Study (48% women; mean age, 50 years), were free of clinical cardiovascular disease, and underwent multidetector computed tomography assessment of SAT and VAT volumes between 2002 and 2005. Metabolic risk factors were examined in relation to increments of SAT and VAT after multivariable adjustment. Heritability was calculated using variance-components analysis. Among both women and men, SAT and VAT were significantly associated with blood pressure, fasting plasma glucose, triglycerides, and high-density lipoprotein cholesterol and with increased odds of hypertension, impaired fasting glucose, diabetes mellitus, and metabolic syndrome (P range < 0.01). In women, relations between VAT and risk factors were consistently stronger than in men. However, VAT was more strongly correlated with most metabolic risk factors than was SAT. For example, among women and men, both SAT and VAT were associated with increased odds of metabolic syndrome. In women, the odds ratio (OR) of metabolic syndrome per 1-standard deviation increase in VAT (OR, 4.7) was stronger than that for SAT (OR, 3.0; P for difference between SAT and VAT < 0.0001); similar differences were noted for men (OR for VAT, 4.2; OR for SAT, 2.5). Furthermore, VAT but not SAT contributed significantly to risk factor variation after adjustment for body mass index and waist circumference (P < or = 0.01). Among overweight and obese individuals, the prevalence of hypertension, impaired fasting glucose, and metabolic syndrome increased linearly and significantly across increasing VAT quartiles. Heritability values for SAT and VAT were 57% and 36%, respectively.
CONCLUSIONS: Although both SAT and VAT are correlated with metabolic risk factors, VAT remains more strongly associated with an adverse metabolic risk profile even after accounting for standard anthropometric indexes. Our findings are consistent with the hypothesized role of visceral fat as a unique, pathogenic fat depot. Measurement of VAT may provide a more complete understanding of metabolic risk associated with variation in fat distribution.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576866     DOI: 10.1161/CIRCULATIONAHA.106.675355

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  989 in total

1.  Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults.

Authors:  Elisa Fabbrini; Robyn A Tamboli; Faidon Magkos; Pamela A Marks-Shulman; Aaron W Eckhauser; William O Richards; Samuel Klein; Naji N Abumrad
Journal:  Gastroenterology       Date:  2010-05-07       Impact factor: 22.682

2.  Visceral adiposity in young patients with coronary artery disease-a case control study.

Authors:  Blessan Varghese; Smrita Swamy; M A Srilakshmi; M J Santhosh; Gurappa G Shetty; Kiron Varghese; Chandrakant B Patil; Shamanna S Iyengar
Journal:  Indian Heart J       Date:  2012 May-Jun

Review 3.  Cardiovascular consequences of obese and nonobese obstructive sleep apnea.

Authors:  Kannan Ramar; Sean M Caples
Journal:  Med Clin North Am       Date:  2010-05       Impact factor: 5.456

4.  Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study.

Authors:  Meredith C Foster; Shih-Jen Hwang; Stacy A Porter; Joseph M Massaro; Udo Hoffmann; Caroline S Fox
Journal:  Hypertension       Date:  2011-09-19       Impact factor: 10.190

5.  Interscan reproducibility of computer-aided epicardial and thoracic fat measurement from noncontrast cardiac CT.

Authors:  Ryo Nakazato; Haim Shmilovich; Balaji K Tamarappoo; Victor Y Cheng; Piotr J Slomka; Daniel S Berman; Damini Dey
Journal:  J Cardiovasc Comput Tomogr       Date:  2011-03-21

6.  Impaired cardiac autonomic nervous system function is associated with pediatric hypertension independent of adiposity.

Authors:  Justin R Ryder; Michael O'Connell; Tyler A Bosch; Lisa Chow; Kyle D Rudser; Donald R Dengel; Claudia K Fox; Julia Steinberger; Aaron S Kelly
Journal:  Pediatr Res       Date:  2015-09-21       Impact factor: 3.756

7.  Heterogeneity in effects of genetically determined adiposity on insulin resistance and type 2 diabetes: The atherosclerosis risk in communities study.

Authors:  Tingting Liu; Changwei Li; Luqi Shen; Ye Shen; Weibo Mao; Shengxu Li
Journal:  J Diabetes Complications       Date:  2018-01-03       Impact factor: 2.852

8.  Mineralocorticoid receptor antagonism prevents obesity-induced cerebral artery remodeling and reduces white matter injury in rats.

Authors:  Paulo W Pires; Jonathon L McClain; Sebastian F Hayoz; Anne M Dorrance
Journal:  Microcirculation       Date:  2018-06-07       Impact factor: 2.628

9.  Experimental Weight Gain Increases Ambulatory Blood Pressure in Healthy Subjects: Implications of Visceral Fat Accumulation.

Authors:  Naima Covassin; Fatima H Sert-Kuniyoshi; Prachi Singh; Abel Romero-Corral; Diane E Davison; Francisco Lopez-Jimenez; Michael D Jensen; Virend K Somers
Journal:  Mayo Clin Proc       Date:  2018-05       Impact factor: 7.616

10.  Automated unsupervised multi-parametric classification of adipose tissue depots in skeletal muscle.

Authors:  Alexander Valentinitsch; Dimitrios C Karampinos; Hamza Alizai; Karupppasamy Subburaj; Deepak Kumar; Thomas M Link; Sharmila Majumdar
Journal:  J Magn Reson Imaging       Date:  2012-10-23       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.